The chemotherapy-induced peripheral neuropathy market is expected to grow from US$ 813.48 million in 2021 to US$ 1,174.26 million by 2028; it is estimated to grow at a CAGR of 5.4% from 2021 to 2028.
The report highlights trends prevailing in the market and factors driving the chemotherapy-induced peripheral neuropathy market growth. The market growth is attributed to a rise in demand for cancer drugs and the use of chemotherapy in earlier stages. However, a lack of awareness regarding the symptoms of chemotherapy-induced peripheral neuropathy limits the market growth.
Peripheral neuropathy is indicated by symptoms that result from damage to the peripheral nerves. These nerves carry sensations, and control arm and leg movements as well as bladder and intestine functions. Chemotherapy and other medications used to treat cancer can cause peripheral neuropathy, which is termed as chemotherapy-induced peripheral neuropathy.
Spending on anticancer drugs is one of the most important factors incurring excess costs in healthcare. Both, chemotherapy and targeted therapy significantly improve the chances of survival among cancer patients, along with improving their quality of life. These therapies may result in the complete remission of a tumor. Owing to these benefits, the demand for chemotherapy has surged globally with the rising burden of cancer. A study published recently in Lancet Oncology states that the number of patients requiring chemotherapy will increase by 53% from 980,000 to 15 million worldwide from 2018 to 2040. Advanced cancer treatments further improve patient survival and increase the number of patients requiring long-term outpatient chemotherapy. More exposure to chemotherapy may result in a greater number of CIPN cases, thereby deriving the chemotherapy-induced peripheral neuropathy market growth.
Based on drug class, the chemotherapy-induced peripheral neuropathy market is segmented into steroids, anti-seizure, narcotics, and anti-depressants. In 2021, the steroids segment held the largest share of the market. However, the anti-seizure segment is expected to register the highest CAGR from 2021 to 2028. Based on distribution channel, the chemotherapy-induced peripheral neuropathy market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest market share in 2021. However, the retail pharmacies segment is anticipated to register the highest CAGR during the forecast period.
COVID-19 Impact - Chemotherapy-Induced Peripheral Neuropathy Market
The COVID-19 pandemic had a major impact on oncology services at a global level during 2020-2021. It disrupted cancer treatment plans as many healthcare providers had to postpone the diagnosis and treatment of cancer cases. Moreover, social restrictions and lockdown measures resulted in the discontinuation of clinical trials.. Further, with the rise in COVID-19 burden, healthcare authorities had to conduct reprofiling of many hospitals and departments, including oncology clinics, for treating a large volume of patients. For Instance, in the Netherlands, cancer registry data show a significant reduction in cancer diagnosis compared to before the outbreak of COVID-19. In the UK, emergency referrals from primary care for people with suspected cancer reduced by 76%, and chemotherapy appointments for cancer patients decreased by 60% compared to the pre-COVID-19 levels. In France, the number of cancer diagnoses decreased by 35-50% in April 2020 compared to April 2019. As a result, disruptions in healthcare operations hampered the growth of the chemotherapy induced peripheral neuropathy market progress in 2020, due to the low number of chemotherapy sessions conducted during this period.
Various organic and inorganic strategies are adopted by companies in the chemotherapy-induced peripheral neuropathy market. The organic strategies mainly include product launches and product approvals. Further, inorganic growth strategies witnessed in the market are acquisitions, collaboration, and partnerships. These growth strategies allow the chemotherapy-induced peripheral neuropathy market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall market growth. Further, acquisition and partnership strategies help the market players in strengthening their customer base and expanding their product portfolios. A few of the significant developments by key players in the chemotherapy-induced peripheral neuropathy market are listed below.
- In April 2021, WEX Pharmaceuticals Inc. announced that two clinical trials on tetrodotoxin (TTX) as a therapeutic agent had been published in a special issue of the Toxins Journal. The cardiac safety study "Safety, Tolerability, Pharmacokinetics, and Concentration-QTc Analysis of Tetrodotoxin: A Randomized, Dose Escalation Study in Healthy Adults" was included in the special edition of the Toxins Journal, as was the study "Tetrodotoxin for Chemotherapy-Induced Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Dose Finding WEX.”
- In December 2020, Regenacy announced a joint venture with 3E Bioventures for the development of ricolinostat in China, which will be followed by a US-based phase 2 study in patients with painful diabetic peripheral neuropathy and other peripheral neuropathies. BC Regenacy’s lead program will evaluate the efficacy and safety of ricolinostat in patients with chemotherapy-induced peripheral neuropathy in China.
A few of the major primary and secondary sources referred to while preparing the report on the chemotherapy-induced peripheral neuropathy market are the World Health Organization (WHO), the Centers for Disease Control (CDC), and the Association of the British Pharmaceutical Industry (ABPI).
The report highlights trends prevailing in the market and factors driving the chemotherapy-induced peripheral neuropathy market growth. The market growth is attributed to a rise in demand for cancer drugs and the use of chemotherapy in earlier stages. However, a lack of awareness regarding the symptoms of chemotherapy-induced peripheral neuropathy limits the market growth.
Peripheral neuropathy is indicated by symptoms that result from damage to the peripheral nerves. These nerves carry sensations, and control arm and leg movements as well as bladder and intestine functions. Chemotherapy and other medications used to treat cancer can cause peripheral neuropathy, which is termed as chemotherapy-induced peripheral neuropathy.
Spending on anticancer drugs is one of the most important factors incurring excess costs in healthcare. Both, chemotherapy and targeted therapy significantly improve the chances of survival among cancer patients, along with improving their quality of life. These therapies may result in the complete remission of a tumor. Owing to these benefits, the demand for chemotherapy has surged globally with the rising burden of cancer. A study published recently in Lancet Oncology states that the number of patients requiring chemotherapy will increase by 53% from 980,000 to 15 million worldwide from 2018 to 2040. Advanced cancer treatments further improve patient survival and increase the number of patients requiring long-term outpatient chemotherapy. More exposure to chemotherapy may result in a greater number of CIPN cases, thereby deriving the chemotherapy-induced peripheral neuropathy market growth.
Based on drug class, the chemotherapy-induced peripheral neuropathy market is segmented into steroids, anti-seizure, narcotics, and anti-depressants. In 2021, the steroids segment held the largest share of the market. However, the anti-seizure segment is expected to register the highest CAGR from 2021 to 2028. Based on distribution channel, the chemotherapy-induced peripheral neuropathy market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest market share in 2021. However, the retail pharmacies segment is anticipated to register the highest CAGR during the forecast period.
COVID-19 Impact - Chemotherapy-Induced Peripheral Neuropathy Market
The COVID-19 pandemic had a major impact on oncology services at a global level during 2020-2021. It disrupted cancer treatment plans as many healthcare providers had to postpone the diagnosis and treatment of cancer cases. Moreover, social restrictions and lockdown measures resulted in the discontinuation of clinical trials.. Further, with the rise in COVID-19 burden, healthcare authorities had to conduct reprofiling of many hospitals and departments, including oncology clinics, for treating a large volume of patients. For Instance, in the Netherlands, cancer registry data show a significant reduction in cancer diagnosis compared to before the outbreak of COVID-19. In the UK, emergency referrals from primary care for people with suspected cancer reduced by 76%, and chemotherapy appointments for cancer patients decreased by 60% compared to the pre-COVID-19 levels. In France, the number of cancer diagnoses decreased by 35-50% in April 2020 compared to April 2019. As a result, disruptions in healthcare operations hampered the growth of the chemotherapy induced peripheral neuropathy market progress in 2020, due to the low number of chemotherapy sessions conducted during this period.
Various organic and inorganic strategies are adopted by companies in the chemotherapy-induced peripheral neuropathy market. The organic strategies mainly include product launches and product approvals. Further, inorganic growth strategies witnessed in the market are acquisitions, collaboration, and partnerships. These growth strategies allow the chemotherapy-induced peripheral neuropathy market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall market growth. Further, acquisition and partnership strategies help the market players in strengthening their customer base and expanding their product portfolios. A few of the significant developments by key players in the chemotherapy-induced peripheral neuropathy market are listed below.
- In April 2021, WEX Pharmaceuticals Inc. announced that two clinical trials on tetrodotoxin (TTX) as a therapeutic agent had been published in a special issue of the Toxins Journal. The cardiac safety study "Safety, Tolerability, Pharmacokinetics, and Concentration-QTc Analysis of Tetrodotoxin: A Randomized, Dose Escalation Study in Healthy Adults" was included in the special edition of the Toxins Journal, as was the study "Tetrodotoxin for Chemotherapy-Induced Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Dose Finding WEX.”
- In December 2020, Regenacy announced a joint venture with 3E Bioventures for the development of ricolinostat in China, which will be followed by a US-based phase 2 study in patients with painful diabetic peripheral neuropathy and other peripheral neuropathies. BC Regenacy’s lead program will evaluate the efficacy and safety of ricolinostat in patients with chemotherapy-induced peripheral neuropathy in China.
A few of the major primary and secondary sources referred to while preparing the report on the chemotherapy-induced peripheral neuropathy market are the World Health Organization (WHO), the Centers for Disease Control (CDC), and the Association of the British Pharmaceutical Industry (ABPI).
Table of Contents
1. Introduction1.1 Scope of the Study
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 Global Chemotherapy Induced Peripheral Neuropathy Market - By Drug Class
1.3.2 Global Chemotherapy Induced Peripheral Neuropathy Market - By Distribution Channel
1.3.3 Global Chemotherapy Induced Peripheral Neuropathy Market - By Geography
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Chemotherapy Induced Peripheral Neuropathy Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.2.2 Europe PEST Analysis
4.2.3 Asia Pacific PEST Analysis
4.2.4 Middle East And Africa PEST Analysis
4.2.5 South And Central America PEST Analysis
4.3 Experts Opinion
5. Chemotherapy Induced Peripheral Neuropathy Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Cancer
5.1.2 Increasing Preference for Chemotherapy
5.2 Market Restraints
5.2.1 Lack of Consolidated Guidelines for Chemotherapy
5.3 Market Opportunities
5.3.1 Emerging Markets in Developing Countries
5.4 Future Trends
5.4.1 Rising Clinical Trails for Chemotherapeutic Drugs
5.5 Impact Analysis
6. Chemotherapy Induced Peripheral Neuropathy Market- Global Analysis
6.1 Global Chemotherapy Induced Peripheral Neuropathy Market Revenue Forecast And Analysis
6.1.1 Global Chemotherapy Induced Peripheral Neuropathy Market Revenue Forecast And Analysis
6.1.2 Global Chemotherapy Induced Peripheral Neuropathy Market - Market Potential Analysis, By Region
6.2 Market Positioning Analysis Of Key Players In Chemotherapy Induced Peripheral Neuropathy Market
6.2.1 Company Analysis
6.2.2 Growth Strategy Analysis
6.2.3 Performance Of Key Players
6.2.3.1 Wex Pharmaceuticals Inc.
6.2.3.2 Regenacy Pharmaceuticals, Inc.
7. Global Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts To 2028- by Drug Class
7.1 Overview
7.2 Drug Class Market Revenue and Forecast Analysis (US$ Mn)
7.3 Steroids
7.3.1 Overview
7.3.2 Steroids Revenue and Forecast to 2028 (US$ Mn)
7.4 Antidepressants
7.4.1 Overview
7.4.2 Antidepressants Revenue and Forecast to 2028 (US$ Mn)
7.5 Anti-seizure. Error! Bookmark not defined.7.5.1 Overview7.5.2 Anti-seizure Revenue and Forecast to 2028 (US$ Mn)
7.6 Narcotics
7.6.1 Overview
7.6.2 Narcotics Revenue and Forecast to 2028 (US$ Mn)
8. Global Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Analysis and Forecast to 2028 - by Distribution Channel
8.1 Overview
8.2 Distribution Channel Market Revenue and Forecast Analysis (US$ Mn)
8.3 Hospital Pharmacy
8.3.1 Overview
8.3.2 Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
8.4 Retail Pharmacy
8.4.1 Overview
8.4.2 Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
8.5 Online Pharmacy
8.5.1 Overview
8.5.2 Online Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
9. Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 - Geographical Analysis
9.1 North America: Chemotherapy Induced Peripheral Neuropathy Market
9.1.1 Overview
9.1.2 North America: Chemotherapy Induced Peripheral Neuropathy Market - Revenue and Forecast to 2028 (US$ Million)
9.1.3 North America: Chemotherapy Induced Peripheral Neuropathy Market, by Drug Class, 2019- 2028 (US$ Million)
9.1.4 North America: Chemotherapy Induced Peripheral Neuropathy Market, by Distribution Channel, 2019- 2028 (US$ Million)
9.1.5 North America: Chemotherapy Induced Peripheral Neuropathy Market, by Country, 2021 & 2028 (%)
9.1.5.1 US: Chemotherapy Induced Peripheral Neuropathy Market - Revenue and Forecast to 2028 (US$ Million)
9.1.5.1.1 US: Chemotherapy Induced Peripheral Neuropathy Market - Revenue and Forecast to 2028 (US$ Million)
9.1.5.1.2 US: Chemotherapy Induced Peripheral Neuropathy Market, by Drug Class, 2019- 2028 (US$ Million)
9.1.5.1.3 US: Chemotherapy Induced Peripheral Neuropathy Market, by Distribution Channel, 2019- 2028 (US$ Million)
9.1.5.2 Canada: Chemotherapy Induced Peripheral Neuropathy Market - Revenue and Forecast to 2028 (US$ Million)
9.1.5.2.1 Canada: Chemotherapy Induced Peripheral Neuropathy Market - Revenue and Forecast to 2028 (US$ Million)
9.1.5.2.2 Canada: Chemotherapy Induced Peripheral Neuropathy Market, by Drug Class, 2019- 2028 (US$ Million)
9.1.5.2.3 Canada: Chemotherapy Induced Peripheral Neuropathy Market, by Distribution Channel, 2019- 2028 (US$ Million)
9.1.5.3 Mexico: Chemotherapy Induced Peripheral Neuropathy Market - Revenue and Forecast to 2028 (US$ Million)
9.1.5.3.1 Mexico: Chemotherapy Induced Peripheral Neuropathy Market - Revenue and Forecast to 2028 (US$ Million)
9.1.5.3.2 Mexico: Chemotherapy Induced Peripheral Neuropathy Market, by Drug Class, 2019- 2028 (US$ Million)
9.1.5.3.3 Mexico: Chemotherapy Induced Peripheral Neuropathy Market, by Distribution Channel, 2019- 2028 (US$ Million)
9.2 Europe: Chemotherapy- Induced Peripheral Neuropathy Market
9.2.1 Overview
9.2.2 Europe: Chemotherapy- Induced Peripheral Neuropathy Market - Revenue and Forecast to 2028 (US$ Million)
9.2.3 Europe: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class, 2019- 2028 (US$ Million)
9.2.4 Europe: Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel, 2019- 2028 (US$ Million)
9.2.5 Europe: Chemotherapy- Induced Peripheral Neuropathy Market, by Country, 2021 & 2028 (%)
9.2.5.1 Germany: Chemotherapy- Induced Peripheral Neuropathy Market - Revenue and Forecast to 2028 (US$ Million)
9.2.5.1.1 Germany: Chemotherapy- Induced Peripheral Neuropathy Market - Revenue and Forecast to 2028 (US$ Million)
9.2.5.1.2 Germany: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class, 2019- 2028 (US$ Million)
9.2.5.1.3 Germany: Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel, 2019- 2028 (US$ Million)
9.2.5.2 France: Chemotherapy- Induced Peripheral Neuropathy Market - Revenue and Forecast to 2028 (US$ Million)
9.2.5.2.1 France: Chemotherapy- Induced Peripheral Neuropathy Market - Revenue and Forecast to 2028 (US$ Million)
9.2.5.2.2 France: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class, 2019- 2028 (US$ Million)
9.2.5.2.3 France: Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel, 2019- 2028 (US$ Million)
9.2.5.3 UK: Chemotherapy- Induced Peripheral Neuropathy Market - Revenue and Forecast to 2028 (US$ Million)
9.2.5.3.1 UK: Chemotherapy- Induced Peripheral Neuropathy Market - Revenue and Forecast to 2028 (US$ Million)
9.2.5.3.2 UK: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class, 2019- 2028 (US$ Million)
9.2.5.3.3 UK: Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel, 2019- 2028 (US$ Million)
9.2.5.4 Italy: Chemotherapy- Induced Peripheral Neuropathy Market - Revenue and Forecast to 2028 (US$ Million)
9.2.5.4.1 Italy: Chemotherapy- Induced Peripheral Neuropathy Market - Revenue and Forecast to 2028 (US$ Million)
9.2.5.4.2 Italy: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class, 2019- 2028 (US$ Million)
9.2.5.4.3 Italy: Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel, 2019- 2028 (US$ Million)
9.2.5.5 Spain: Chemotherapy- Induced Peripheral Neuropathy Market - Revenue and Forecast to 2028 (US$ Million)
9.2.5.5.1 Spain: Chemotherapy- Induced Peripheral Neuropathy Market - Revenue and Forecast to 2028 (US$ Million)
9.2.5.5.2 Spain: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class, 2019- 2028 (US$ Million)
9.2.5.5.3 Spain: Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel, 2019- 2028 (US$ Million)
9.2.5.6 Rest of Europe: Chemotherapy- Induced Peripheral Neuropathy Market - Revenue and Forecast to 2028 (US$ Million)
9.2.5.6.1 Rest of Europe: Chemotherapy- Induced Peripheral Neuropathy Market - Revenue and Forecast to 2028 (US$ Million)
9.2.5.6.2 Rest of Europe: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class, 2019- 2028 (US$ Million)
9.2.5.6.3 Rest of Europe: Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel, 2019- 2028 (US$ Million)
9.3 Asia Pacific: Chemotherapy- Induced Peripheral Neuropathy Market
9.3.1 Overview
9.3.2 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)
9.3.3 Asia Pacific: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Drug Class (US$ Million)
9.3.4 Asia Pacific: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Million)
9.3.5 Asia Pacific: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Country (%)
9.3.5.1 Japan: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)
9.3.5.1.1 Overview
9.3.5.1.2 Japan: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)
9.3.5.1.3 Japan: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Drug Class (US$ Million)
9.3.5.1.4 Japan: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Million)
9.3.5.2 China: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)
9.3.5.2.1 Overview
9.3.5.2.2 China: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)
9.3.5.2.3 China: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Drug Class (US$ Million)
9.3.5.2.4 China: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Million)
9.3.5.3 India Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)
9.3.5.3.1 Overview
9.3.5.3.2 India: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)
9.3.5.3.3 India: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Drug Class (US$ Million)
9.3.5.3.4 India: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Million)
9.3.5.4 South Korea: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)
9.3.5.4.1 Overview
9.3.5.4.2 South Korea: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)
9.3.5.4.3 South Korea: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Drug Class (US$ Million)
9.3.5.4.4 South Korea: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Million)
9.3.5.5 Australia: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)
9.3.5.5.1 Overview
9.3.5.5.2 Australia: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)
9.3.5.5.3 Australia: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Drug Class (US$ Million)
9.3.5.5.4 Australia: Chemotherapy Induced Peripheral Neuropathy Market, by Sub-Drug Class, 2019- 2028 (US$ Million)
9.3.5.6 Rest of Asia Pacific: Chemotherapy Induced Peripheral Neuropathy Market - Revenue and Forecast to 2028 (US$ Million)
9.3.5.6.1 Overview
9.3.5.6.2 Rest of Asia Pacific: Chemotherapy Induced Peripheral Neuropathy Market - Revenue and Forecast to 2028 (US$ Million)
9.3.5.6.3 Rest of Asia Pacific: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Drug Class (US$ Million)
9.3.5.6.4 Rest of Asia Pacific: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Million)
9.4 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy (CIPN) Market
9.4.1 Overview
9.4.2 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecast to 2028 (US$ Million)
9.4.3 Middle East & Africa: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028, by Product (US$ Million)
9.4.4 Middle East & Africa: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market, by Distribution Channel- Revenue and Forecast to 2028 (US$ Million)
9.4.5 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028, by Country (%)
9.4.5.1 UAE: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecast to 2028 (US$ Million)
9.4.5.1.1 UAE: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028 (US$ Million)
9.4.5.1.2 UAE: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028, by Drug Class (US$ Million)
9.4.5.1.3 UAE: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market, by Distribution Channel- Revenue and Forecast to 2028 (US$ Million)
9.4.5.2 Saudi Arabia: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecast to 2028 (US$ Million)
9.4.5.2.1 Saudi Arabia: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028 (US$ Million)
9.4.5.2.2 Saudi Arabia: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028, by Drug Class (US$ Million)
9.4.5.2.3 Saudi Arabia: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market, by Distribution Channel- Revenue and Forecast to 2028 (US$ Million)
9.4.5.3 South Africa: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028 (US$ Million)
9.4.5.3.1 South Africa Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028 (US$ Million)
9.4.5.3.2 South Africa: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028, by Drug Class (US$ Million)
9.4.5.3.3 South Africa: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
9.4.5.4 Rest of Middle East & Africa: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecast to 2028 (US$ Million)
9.4.5.4.1 Rest of Middle East & Africa: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028 (US$ Million)
9.4.5.4.2 Rest of Middle East & Africa: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028, by Drug Class (US$ Million)
9.4.5.4.3 Rest of Middle East & Africa: D Chemotherapy Induced Peripheral Neuropathy (CIPN) Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
9.5 South and Central America: Chemotherapy- Induced Peripheral Neuropathy Market
9.5.1 Overview
9.5.2 South and Central America: Chemotherapy- Induced Peripheral Neuropathy Market- Revenue and Forecast to 2028 (USD Million)
9.5.3 South and Central America Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class- Revenue and Forecast to 2028 (USD Million)
9.5.4 South and Central America Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
9.5.5 South and Central America: Chemotherapy- Induced Peripheral Neuropathy Market, by Country, 2021 & 2028 (%)
9.5.5.1 Brazil: Chemotherapy- Induced Peripheral Neuropathy Market- Revenue and Forecast to 2028 (USD Million)
9.5.5.2 Brazil: Chemotherapy- Induced Peripheral Neuropathy Market- Revenue and Forecast to 2028 (USD Million)
9.5.5.2.1 Brazil Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class- Revenue and Forecast to 2028 (USD Million)
9.5.5.2.2 Brazil Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
9.5.5.3 Argentina: Chemotherapy- Induced Peripheral Neuropathy Market- Revenue and Forecast to 2028 (USD Million)
9.5.5.3.1 Argentina: Chemotherapy- Induced Peripheral Neuropathy Market- Revenue and Forecast to 2028 (USD Million)
9.5.5.3.2 Argentina Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class- Revenue and Forecast to 2028 (USD Million)
9.5.5.3.3 Argentina Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
9.5.5.4 Rest of South and Central America: Chemotherapy- Induced Peripheral Neuropathy Market- Revenue and Forecast to 2028 (USD Million)
9.5.5.4.1 Rest of South and Central America: Chemotherapy- Induced Peripheral Neuropathy Market- Revenue and Forecast to 2028 (USD Million)
9.5.5.4.2 Rest of South and Central America: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class- Revenue and Forecast to 2028 (USD Million)
9.5.5.4.3 Rest of South and Central America: Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
10. Impact Of COVID-19 Pandemic on Chemotherapy Induced Peripheral Neuropathy Market
10.1 North America: Impact Assessment of COVID-19 Pandemic
10.2 Europe: Impact Assessment of COVID-19 Pandemic
10.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
10.4 Middle East and Africa: Impact Assessment of COVID-19 Pandemic
10.5 South and Central America: Impact Assessment of COVID-19 Pandemic
11. Chemotherapy Induced Peripheral Neuropathy Market- Industry Landscape
11.1 Overview
11.2 Growth Strategies Done by the Companies in the Market, (%)
11.3 Organic Developments
11.3.1 Overview
11.4 Inorganic Developments
11.4.1 Overview
12. Company Profiles
12.1 REGENACY PHARMACEUTICALS, INC.
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Asahi Kasei Pharma Corporation
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Novaremed AG
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 MAKScientific, LLC
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 WEX Pharmaceuticals Inc.
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Sova Pharmaceuticals, Inc.
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Kineta, Inc.
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Aptinyx Inc.
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Apexian Pharmaceuticals, Inc.
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 WinSanTor, Inc.
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Financial Overview
12.10.4 SWOT Analysis
12.10.5 Key Developments
13. Appendix
13.1 About the Publisher
13.2 Glossary of Terms
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- REGENACY PHARMACEUTICALS, INC
- ASAHI KASEI PHARMA CORPORATION
- NOVAREMED
- MAKSCIENTIFIC, LLC
- WEX PHARMACEUTICALS INC
- SOVA PHARMACEUTICALS, INC
- KINETA, INC.
- APTINYX INC.
- APEXIAN PHARMACEUTICALS, INC.
- WINSANTOR, INC
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 151 |
| Published | May 2022 |
| Forecast Period | 2021 - 2028 |
| Estimated Market Value ( $ | $ 813.48 million |
| Forecasted Market Value ( $ | $ 1174.26 million |
| Compound Annual Growth Rate | 5.4% |
| Regions Covered | Global |
